Therapeutic agent for iNOS generating illness
A therapeutic agent which removes or neutralizes iNOS in the blood of a mammalian subject. The agent may be in the form of an anti-iNOS monoclonal antibody or an INOS binding entity.
1 - 11 . (canceled)
12 . A therapeutic agent for the treatment of an illness in a mammalian subject generating iNOS in its blood, comprising:
and iNOS binding entity.
13 . The therapeutic agent of claim 12 in which said iNOS binding entity is selected from the group consisting essentially of: iNOS binding aptamers, oligonucleotides, artificial antibodies, phage displayed antibodies, phage displayed antibody fragments, and single-chain monoclonal antibodies.
14 . The therapeutic agent of claim 12 in which said iNOS binding entity comprises a particulate iNOS neutralizing binding entity, and the particulate iNOS is selected from the group consisting essentially of: particulate membrane-associated iNOS, particulate vesicle associated iNOS, and particulate iNOS in association with at least another protein.
15 . The therapeutic agent of claim 12 which further comprises means for removing the iNOS from the mammalian subject in association with the said iNOS binding entity.
16 . The therapeutic agent of claim 15 in which said means for removing iNOS from the mammalian subject in association with said iNOS binding entity includes: a device coated with a binding entity recognizing human iNOS.
17 . The therapeutic agent of claim 12 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
18 . The therapeutic agent of claim 13 which further comprises means for removing the iNOS from the mammalian subject in association with the said iNOS binding entity.
19 . The therapeutic agent of claim 18 in which said means for removing iNOS from the mammalian subject in association with said iNOS binding entity includes: a device coated with a binding entity recognizing human iNOS.
20 . The therapeutic agent of claim 13 in which said iNOS binding entity comprises a particulate iNOS neutralizing binding entity, and the particulate iNOS is selected from the group consisting essentially of: particulate membrane-associated iNOS, particulate vesicle associated iNOS, and particulate iNOS in association with at least another protein.
21 . The therapeutic agent of claim 13 in which the illness is selected from the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
22 . A composition for diagnosing an illness in mammalian subjects generating iNOS in the blood,
comprising:
an immunostained iNOS form.
23 . The composition of claim 22 in which said immunostained iNOS form comprises extracellular vesicle associated iNOS.
24 . The composition of claim 22 in which the illness comprises systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
25 . A method for treating an illness in a mammalian subject generating iNOS in its blood,
comprising the step of:
interacting the blood of the mammalian subject with a monoclonal antibody recognizing human iNOS.
26 . A method for treating an illness in a mammalian subject generating iNOS in its blood,
comprising the step of:
interacting the blood of the mammalian subject with an iNOS binding entity.
27 . A therapeutic agent for the treatment of an illness generating iNOS in the blood of a mammalian subject,
comprising:
a monoclonal antibody recognizing human iNOS.
28 . The agent of claim 27 in which said monoclonal antibody recognizing human iNOS comprises a particulate iNOS neutralizing monoclonal antibody, and the particulate iNOS is selected from the group consisting essentially of: particulate membrane-associated iNOS, particulate vesicle associated iNOS, and particulate iNOS in association with at least another protein.
29 . The agent of claim 27 in which the illness is selected form the group consisting essentially of:
systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
30 . The agent of claim 27 in which said monoclonal antibody is selected from the group consisting essentially of mouse anti-iNOS monoclonal antibody, mouse-human chimeric anti-iNOS monoclonal antibody, humanized anti-iNOS monoclonal antibody, and human anti-iNOS monoclonal antibody.
31 . The agent of claim 27 which further comprises means for removing the iNOS from the mammalian subject in association with said monoclonal antibody recognizing human iNOS.
32 . The agent of claim 31 in which the iNOS comprises particulate iNOS and is selected form the group consisting essentially of: particulate membrane associated iNOS, particulate vesicle-associated iNOS, and particulate iNOS in association with at least another protein.
33 . The agent of claim 31 in which the illness is selected form the group consisting essentially of: systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
34 . The agent of claim 31 in which said monoclonal antibody is selected from the group consisting essentially of mouse anti-iNOS monoclonal antibody, mouse-human chimeric anti-iNOS monoclonal antibody, humanized anti-iNOS monoclonal antibody, and human anti-iNOS monoclonal antibody.
35 . The agent of claim 31 in which said means for removing the iNOS from the mammalian subject in association with said monoclonal antibody includes: a device coated with a monoclonal antibody recognizing human iNOS.
36 . The agent of claim 35 in which the illness is selected from the group consisting essentially of:
systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.
37 . The agent of claim 35 in which said monoclonal antibody is selected from the group consisting essentially of: mouse anti-iNOS monoclonal antibody, mouse-human chimeric antibody, and human anti-iNOS monoclonal antibody, humanized anti-iNOS monoclonal antibody, and human anti-iNOS monoclonal antibody.
38 . The agent of claim 35 in which said monoclonal antibody recognizing human iNOS comprises a particulate iNOS neutralizing monoclonal antibody, and the particulate iNOS is selected from the group consisting essentially of: particulate membrane-associated iNOS, particulate vesicle associated iNOS, and particulate iNOS in association with at least another protein.